Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.
/PRNewswire/ Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws.
Pfizer is dropping $5.4 billion to acquire Global Blood Therapeutics. Just ahead of the weekend, word got out that Pfizer was close to clinching a $5 billion buyout albeit with other potential. #bpfizer #pfizer #pharmagiant